Tags

Type your tag names separated by a space and hit enter

Migraine headaches: treatment limitations and opportunities.
Postgrad Med. 2006 Apr; Spec No:14-9.PM

Abstract

In recent years, migraine treatment options have expanded to the extent that the practicing clinician now has a myriad of pharmacologic agents in varied drug classes and delivery systems from which to choose. Drug classes most commonly employed for treatment of migraine attacks include non-migraine-specific agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, barbiturates, combination analgesics, and antiemetics, and migraine-specific agents, such as triptans and ergot alkaloids and derivatives. Delivery options range from conventional, orally disintegrating, and rapid-release tablets to injection, nasal spray, and suppository. The US Headache Consortium offers guidelines classifying migraine treatments into different groups based on evidence of clinical benefit (Table 1). Clinicians must be aware of the advantages and limitations of each class and delivery system and possible opportunities to improve their usefulness in different clinical contexts.

Authors

No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

17957856

Citation

Kaniecki, Robert G., and Susan Hutchinson. "Migraine Headaches: Treatment Limitations and Opportunities." Postgraduate Medicine, vol. Spec No, 2006, pp. 14-9.
Kaniecki RG, Hutchinson S. Migraine headaches: treatment limitations and opportunities. Postgrad Med. 2006;Spec No:14-9.
Kaniecki, R. G., & Hutchinson, S. (2006). Migraine headaches: treatment limitations and opportunities. Postgraduate Medicine, Spec No, 14-9.
Kaniecki RG, Hutchinson S. Migraine Headaches: Treatment Limitations and Opportunities. Postgrad Med. 2006;Spec No:14-9. PubMed PMID: 17957856.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Migraine headaches: treatment limitations and opportunities. AU - Kaniecki,Robert G, AU - Hutchinson,Susan, PY - 2007/10/26/pubmed PY - 2007/11/7/medline PY - 2007/10/26/entrez SP - 14 EP - 9 JF - Postgraduate medicine JO - Postgrad Med VL - Spec No N2 - In recent years, migraine treatment options have expanded to the extent that the practicing clinician now has a myriad of pharmacologic agents in varied drug classes and delivery systems from which to choose. Drug classes most commonly employed for treatment of migraine attacks include non-migraine-specific agents, such as nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, barbiturates, combination analgesics, and antiemetics, and migraine-specific agents, such as triptans and ergot alkaloids and derivatives. Delivery options range from conventional, orally disintegrating, and rapid-release tablets to injection, nasal spray, and suppository. The US Headache Consortium offers guidelines classifying migraine treatments into different groups based on evidence of clinical benefit (Table 1). Clinicians must be aware of the advantages and limitations of each class and delivery system and possible opportunities to improve their usefulness in different clinical contexts. SN - 0032-5481 UR - https://www.unboundmedicine.com/medline/citation/17957856/Migraine_headaches:_treatment_limitations_and_opportunities_ L2 - http://www.diseaseinfosearch.org/result/4811 DB - PRIME DP - Unbound Medicine ER -